Clinical Trials Browser

OTHER × Nasopharyngeal Neoplasms × tislelizumab × Clear all

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms